Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a β-arrestin2/Src/Akt signaling complex in vivo

Journal of Neuroscience

Volumn 30, Issue 40, 2010, Pages 13513-13524

  Schmid, Cullen L ^a,b   Bohn, Laura M ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; BETA ARRESTIN 2; METHYLTRANSFERASE; N METHYLSEROTONIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SEROTONIN; SEROTONIN 2A RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FRONTAL CORTEX; HEAD TWITCH; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; ANIMALS, NEWBORN; ARRESTINS; CELLS, CULTURED; FRONTAL LOBE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; SYNAPTIC TRANSMISSION; TRYPTAMINES;

EID: 77957742904     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1665-10.2010     Document Type: Article

References (77)

1. Abbas AI, Yadav PN, Yao WD, Arbuckle MI, Grant SG, Caron MG, Roth BL (2009) PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J Neurosci 29:7124-7136.
2. Aghajanian GK, Marek GJ (1999) Serotonin and hallucinogens. Neuropsychopharmacology 21:16S-23S.
3. Angrist B, Thompson H, Shopsin B, Gershon S (1975) Clinical studies with dopamine-receptor stimulants. Psychopharmacologia 44:273-280.
4. Arnt J, Hyttel J (1989) Facilitation of 8-OHDPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI. Eur J Pharmacol 161:45-51. (Pubitemid 19058846)
5. Askwith CC, Wemmie JA, Price MP, Rokhlina T, Welsh MJ (2004) Acid-sensing ion channel 2 (ASIC2) modulates ASIC1 H+-activated currents in hippocampal neurons. J Biol Chem 279:18296-18305. (Pubitemid 38623244)
6. Axelrod J (1962) The enzymatic N-methylation of serotonin and other amines. J Pharmacol Exp Ther 138:28-33.
7. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122:261-273. (Pubitemid 41032989)
8. Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V, Wetsel WC, Lefkowitz RJ, Gainetdinov RR, Caron MG (2008) A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132:125-136.
9. Berendsen HH, Broekkamp CL (1991) Attenuation of 5-HT1A and 5-HT2 but not 5-HT1C receptor mediated behaviour in rats following chronic treatment with 5-HT receptor agonists, antagonists or anti-depressants. Psychopharmacology (Berl) 105:219-224.
10. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94-104. (Pubitemid 28337591)
11. Berg KA, Harvey JA, Spampinato U, Clarke WP (2008) Physiological and therapeutic relevance of constitutive activity of 5-HT 2A and 5-HT 2C receptors for the treatment of depression. Prog Brain Res 172:287-305.
12. Bidder TG, Mandel LR, Ahn HS, Vanden Heuvel WJ, Walker RW (1974) Letter: blood and urinary dimethyltryptamine in acute psychotic disorders. Lancet 1:165.
13. Blair JB, Kurrasch-Orbaugh D, Marona-Lewicka D, Cumbay MG, Watts VJ, Barker EL, Nichols DE (2000) Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem 43:4701-4710.
14. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT (1999) Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286:2495-2498.
15. Borchardt RT, Wu YS (1976) Potential inhibitors of S-adenosylmethionine- dependent methyltransferases. 5. Role of the asymmetric sulfonium pole in the enzymatic binding of S-adenosyl-L-methionine. J Med Chem 19:1099-1103.
16. Boyer EW, Shannon M (2005) The serotonin syndrome. N Engl J Med 352:1112-1120.
17. Breivogel CS, Lambert JM, Gerfin S, Huffman JW, Razdan RK (2008) Sensitivity to delta9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2-/- mice. Behav Pharmacol 19:298-307.
18. Canal CE, Olaghere da Silva UB, Gresch PJ, Watt EE, Sanders-Bush E, Airey DC (2010) The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen. Psychopharmacology (Berl) 209:163-174.
19. Chen R, Kim O, Yang J, Sato K, Eisenmann KM, McCarthy J, Chen H, Qiu Y (2001) Regulation of Akt/PKB activation by tyrosine phosphorylation. J Biol Chem 276:31858-31862.
20. Corne SJ, Pickering RW (1967) A possible correlation between drug-induced hallucinations in man and a behavioural response in mice. Psychopharmacologia 11:65-78.
21. Corne SJ, Pickering RW, Warner BT (1963) A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine. Br J Pharmacol Chemother 20:106-120.
22. Crooks PA, Dreyer RN, Sulens CH, Gillis CN, Coward JK (1979) Determination of 5-hydroxytryptamine metabolites in isolated perfused rabbit lung by high-performance liquid chromatography. Anal Biochem 93:143-152.
23. Deshpande DA, Theriot BS, Penn RB, Walker JK (2008) Beta-arrestins specifically constrain beta2-adrenergic receptor signaling and function in airway smooth muscle. FASEB J 22:2134-2141.
24. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK (2007) Beta-arrestins and cell signaling. Annu Rev Physiol 69:483-510.
25. Domino EF (1976) Search for new treatment approaches in schizophrenia: in vitro studies of potential N-methyltransferase inhibitors. Arch Int Pharmacodyn Ther 221:75-86.
26. Emanuele E, Colombo R, Martinelli V, Brondino N, Marini M, Boso M, Barale F, Politi P (2010) Elevated urine levels of bufotenine in patients with autistic spectrum disorders and schizophrenia. Neuro Endocrinol Lett 31:117-121.
27. Fan J, Cowan CM, Zhang LY, Hayden MR, Raymond LA (2009) Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease. J Neurosci 29:10928-10938.
28. Garcia EE, Smith RL, Sanders-Bush E (2007) Role of G(q) protein in behavioral effects of the hallucinogenic drug 1-(2,5-dimethoxy-4-iodophenyl)-2- aminopropane. Neuropharmacology 52:1671-1677.
29. Gingerich S, Krukoff TL (2008) Activation of ERbeta increases levels of phosphorylated nNOS and NO production through a Src/PI3K/Akt-dependent pathway in hypothalamic neurons. Neuropharmacology 55:878-885.
30. Glennon RA, Gessner PK (1979) Serotonin receptor binding affinities of tryptamine analogues. J Med Chem 22:428-432.
31. González-Maeso J, Yuen T, Ebersole BJ, Wurmbach E, Lira A, Zhou M, Weisstaub N, Hen R, Gingrich JA, Sealfon SC (2003) Transcriptome fingerprints distinguish hallucinogenicand nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci 23:8836-8843. (Pubitemid 37210895)
32. González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53:439-452. (Pubitemid 46161267)
33. Groer CE, Tidgewell K, Moyer RA, Harding WW, Rothman RB, Prisinzano TE, Bohn LM (2007) An opioid agonist that does not induce mu-opioid receptor-beta-arrestin interactions or receptor internalization. Mol Pharmacol 71:549-557. (Pubitemid 46147920)
34. Hu Q, Klippel A, Muslin AJ, Fantl WJ, Williams LT (1995) Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. Science 268:100-102.
35. Insel TR, Roy BF, Cohen RM, Murphy DL (1982) Possible development of the serotonin syndrome in man. Am J Psychiatry 139:954-955.
36. Jakab RL, Goldman-Rakic PS (1998) 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci U S A 95:735-740.
37. 2+-phosphate transfection efficiency enables single neuron gene analysis. Gene Ther 11:1303-1311.
38. Jiang T, Qiu Y (2003) Interaction between Src and a C-terminal proline-rich motif of Akt is required for Akt activation. J Biol Chem 278:15789-15793. (Pubitemid 36799692)
39. Johnson-Farley NN, Kertesy SB, Dubyak GR, Cowen DS (2005) Enhanced activation of Akt and extracellular-regulated kinase pathways by simultaneous occupancy of Gq-coupled 5-HT2A receptors and Gs-coupled 5-HT7A receptors in PC12 cells. J Neurochem 92:72-82.
40. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos RC, Tran TB, Whaley R, Glennon RA, Hert J, Thomas KL, Edwards DD, Shoichet BK, Roth BL (2009) Predicting new molecular targets for known drugs. Nature 462:175-181.
41. Kenakin T (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238.
42. Kety SS (1959) Biochemical theories of schizophrenia. I. Science 129:1528-1532.
43. Kobilka BK, Deupi X (2007) Conformational complexity of G-protein-coupled receptors. Trends Pharmacol Sci 28:397-406.
44. Kurrasch-Orbaugh DM, Parrish JC, Watts VJ, Nichols DE (2003) A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement of MAP kinases. J Neurochem 86:980-991.
45. Lefkowitz RJ, Rajagopal K, Whalen EJ (2006) New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors. Mol Cell 24:643-652. (Pubitemid 44839219)
46. Lipinski JF, Mandel LR, Ahn HS, Vanden Heuvel WJ, Walker RW (1974) Blood dimethyltryptamine concentrations in psychotic disorders. Biol Psychiatry 9:89-91.
47. Luan B, Zhao J, Wu H, Duan B, Shu G, Wang X, Li D, Jia W, Kang J, Pei G (2009) Deficiency of a beta-arrestin-2 signal complex contributes to insulin resistance. Nature 457:1146-1149.
48. Luttrell LM, Lefkowitz RJ (2002) The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 115:455-465.
49. Magalhaes AC, Holmes KD, Dale LB, Comps-Agrar L, Lee D, Yadav PN, Drysdale L, Poulter MO, Roth BL, Pin JP, Anisman H, Ferguson SS (2010) CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. Nat Neurosci 13:622-629.
50. Mailman RB (2007) GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 28:390-396.
51. Mandel LR, Rokach J, Rooney CS, Cragoe EJ Jr (1978) Inhibition of dimethyltryptamine biosynthesis by N,Ń-bis-(3-methyl-2- thiazolidinylidene) succinamide (I) and 2-imino-3-methylthiazolidine (II). Mol Pharmacol 14:930-939.
52. McBride MC (2000) Bufotenine: toward an understanding of possible psychoactive mechanisms. J Psychoactive Drugs 32:321-331.
53. Meltzer HY (2002) Mechanism of action of atypical antipsychotic drugs. In: Neuropsychopharmacology: the fifth generation of progress (Davis KL, Charney D, Coyle JT, Nemeroff C, eds), pp 819-832. New York: Raven.
54. Miner LA, Backstrom JR, Sanders-Bush E, Sesack SR (2003) Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex. Neuroscience 116:107-117. (Pubitemid 36110438)
55. Moya PR, Berg KA, Gutiérrez-Hernandez MA, Sáez-Briones P, Reyes-Parada M, Cassels BK, Clarke WP (2007) Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J Pharmacol Exp Ther 321:1054-1061. (Pubitemid 46762692)
56. Narita M, Kato H, Kasukawa A, Narita M, Suzuki M, Takeuchi T, Suzuki T (2006) Role of Src family kinase in the rewarding effect and hyperlocomotion induced by morphine. Neuroreport 17:115-119. (Pubitemid 43100311)
57. Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131-181.
58. Pieri L, Keller HH, Burkard W, Da Prada M (1978) Effects of lisuride and LSD on cerebral monoamine systems and hallucinosis. Nature 272:278-280. (Pubitemid 8284704)
59. Rajagopal S, Rajagopal K, Lefkowitz RJ (2010) Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 9:373-386.
60. Rokach J, Girard Y, Hamel P, Reader G, Rooney CS, Mandel LR, Cragoe EJ Jr, Zacchei AG (1980) Inhibitors of indoleethylamine N-methyltransferase. Derivatives of 3-methyl-2-thiazolidinimine. In vitro, in vivo, and metabolic studies. J Med Chem 23:773-780.
61. Rosengarten H, Friedhoff AJ (1976) A review of recent studies of the biosynthesis and excretion of hallucinogens formed by methylation of neurotransmitters or related substances. Schizophr Bull 2:90-105.
62. Roth BL, Hanizavareh SM, Blum AE (2004) Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl) 174:17-24.
63. Saavedra JM, Axelrod J (1972) Psychotomimetic N-methylated tryptamines: formation in brain in vivo and in vitro. Science 175:1365-1366.
64. Schmid CL, Bohn LM (2009) Physiological and pharmacological implications of beta-arrestin regulation. Pharmacol Ther 121:285-293.
65. Schmid CL, Raehal KM, Bohn LM (2008) Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci U S A 105:1079-1084.
66. Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ (1995) (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther 273:101-112.
67. Shulgin A, Shulgin A (1997) TiHKAL: the continuation. Berkeley, CA: Transform.
68. Snyder SH, Banerjee SP, Yamamura HI, Greenberg D (1974) Drugs, neurotransmitters, and schizophrenia. Science 184:1243-1253.
69. Sorensen SM, Kehne JH, Fadayel GM, Humphreys TM, Ketteler HJ, Sullivan CK, Taylor VL, Schmidt CJ (1993) Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 266:684-691.
70. Sternbach H (1991) The serotonin syndrome. Am J Psychiatry 148:705-713.
71. Tadano T, Satoh S, Satoh N, Kisara K, Arai Y, Kim SK, Kinemuchi H (1989) Potentiation of para-hydroxyamphetamine-induced head-twitch response by inhibition of monoamine oxidase type A in the brain. J Pharmacol Exp Ther 250:254-260. (Pubitemid 19194999)
72. Takeda N, Ikeda R, Ohba K, Kondo M (1995) Bufotenine reconsidered as a diagnostic indicator of psychiatric disorders. Neuroreport 6:2378-2380. (Pubitemid 26010073)
73. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13. (Pubitemid 46025713)
74. Violin JD, Lefkowitz RJ (2007) Beta-arrestin-biased ligands at seventransmembrane receptors. Trends Pharmacol Sci 28:416-422.
75. Willins DL, Meltzer HY (1997) Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther 282:699-706.
76. Xia Z, Hufeisen SJ, Gray JA, Roth BL (2003) The PDZ-binding domain is essential for the dendritic targeting of 5-HT2A serotonin receptors in cortical pyramidal neurons in vitro. Neuroscience 122:907-920. (Pubitemid 37485844)
77. Xu X, Chua CC, Gao J, Chua KW, Wang H, Hamdy RC, Chua BH (2008) Neuroprotective effect of humanin on cerebral ischemia/reperfusion injury is mediated by a PI3K/Akt pathway. Brain Res 1227:12-18.